Taliglucerase alfa (Elelyso)

Elelyso (taliglucerase alfa) is covered only for the FDA‑approved treatment of Type 1 Gaucher disease and is not supported for any other indications. Coverage requires documented deficient β‑glucocerebrosidase activity in leukocytes or fibroblasts OR molecular genetic confirmation of a GBA mutation, prescription by or in consultation with a geneticist, endocrinologist, metabolic disorder sub‑specialist or lysosomal storage disorder specialist, approval is for 1 year, and dosing is limited to 60 U/kg IV no more frequently than every 2 weeks.

"Elelyso is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.